Efficacy of oral methotrexate pulsed therapy in Eales disease

Annals of Ophthalmology - Glaucoma

Volumn 32, Issue 1, 2000, Pages 60-62

  Saxena, Sandeep ^a,b   Kumar, Dipak ^b   Kapoor, Sangeeta ^b  

^a G 19 River Bank Colony   (India)

^b UNIVERSITY OF LUCKNOW   (India)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG TOLERABILITY; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA VASCULITIS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 17244364435     PISSN: 10794794     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12009-000-0014-5     Document Type: Article

References (16)

1. Gieser SC, Murphy RP. Eales disease. In: Ryan SJ, ed. Retina. Vol 2: Medical retina. St Louis, Mo: Mosby-Year Book; 1994:1503-1507.
2. Kumar D, Saxena RC, Saxena S. Vitreous hemorrhage in Eales disease. Afro-Asian J Ophthalmol. 1995;13:109-112.
3. Saxena S, Kumar D, Singh VK, Rajasingh J. Immunological studies in Eales disease: a review. Afro-Asian J Ophthalmol. 1995;13: 19-22.
4. Rengarajan K, Muthukkaruppan VR, Namperumalsamy P. Biochemical analysis of serum proteins from Eales' patients. Curr Eye Res. 1989;8:1259-1269.
5. Muthukkaruppan VR, Rengarajan K, Chakkalath HR, Namperumalsamy P. Immunological status of patients of Eales' disease. Ind J Med Res. 1989;90:351-359.
6. Sawhney R, Gupta A, Bansal RK, et al. Eales' disease: an autoimmune retinal disorder. Proc All India Ophthalmol Soc. 1992;50: 461-464.
7. Biswas J, Rao NA. Epiretinal membranes in Eales' disease and other vascular retinopathies. Invest Ophthalmol Vis Sci. 1990;31 (suppl):369.
8. Badrinath SS, Biswas J, Sharma T, et al. Immunophenotyping of inflammatory infiltrates in epiretinal (ERM) and subretinal (SRM) membranes in Eales' disease. Invest Ophthalmol Vis Sci. 1992;33 (suppl):857.
9. Chauber BA, Allegra CJ, Curt GA, Calabresi P. Antineoplastic agents. In: JG Mardman, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:1233-1282.
10. Palmer HE, Stanford MR, Sanders MD, Graham EM. Visual outcome of patients with idiopathic ischaemic and non-ischaemic retinal vasculitis. Eye. 1996;10:343-348.
11. Stanford MR, Graham EM, Kasp E, et al. A longitudinal study of clinical and immunological findings in 52 patients with relapsing retinal vasculitis. Br J Ophthalmol. 1988;72:442-447.
12. Howe LJ, Stanford MR, Edelsten C, Graham EM. The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis. Eye. 1994;8:443-447.
13. Isaacs J, Dick A. Short term immunosuppressive therapy and long term immunoregulation: promises and problems [commentary]. Br J Ophthalmol. 1996;80:1035-1036.
14. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotroxate therapy for ocular inflammatory disease. Ophthalmology. 1992;99: 1419-1423.
15. Meyer PA, Watson PG, Franks W, Dubord P. Pulsed immunosuppreasive therapy in the treatment of immunologically induced corneal and scleral disease. Eye. 1987;1:487-495.
16. Mime CA, Playfair JHL, Roitt IMR, et al. The innate defenses of the body. In: Medical Microbiology. St Louis, Mo: Mosby-Year Book; 1993:4.1-4.14.